Lung Cancer Genomic Testing Market: Business Scenario, Industry Study, and Competitive Landscape Review, Forecast to 2033
Straits Research Publishes Groundbreaking Report on Lung Cancer Genomic Testing Market
Global Lung Cancer Genomic Testing Market Set to Reach USD 2.47 Billion by 2032, Growing at a CAGR of 8%
Straits Research, a leading market research company, has released an extensive report on the global lung cancer genomic testing market. Valued at USD 1.21 billion in 2023, the market is poised for significant growth, reaching USD 2.47 billion by 2032. This growth reflects a compound annual growth rate (CAGR) of 8% during the forecast period from 2024 to 2032. With increasing awareness and advancements in genomic technologies, the market is expected to thrive, offering enhanced diagnostic and therapeutic approaches for lung cancer patients worldwide.
Market Definition: The lung cancer genomic testing market is driven by the growing demand for advanced diagnostic tests for lung cancer, focusing on the genetic variations and mutations that are crucial for personalized treatment. Genomic testing involves analyzing the DNA of lung cancer cells to identify mutations and genetic alterations that influence treatment decisions. These tests are essential for developing targeted therapies, improving patient outcomes, and optimizing treatment strategies for lung cancer patients.
Latest 3 Trends Shaping the Market:
-
Increasing Adoption of Liquid Biopsy: Liquid biopsy is gaining momentum as a non-invasive alternative to tissue biopsy, enabling early detection of lung cancer through blood samples. This trend is expected to drive the demand for genomic testing in the coming years, as it offers a less risky and more accessible method for monitoring cancer progression and treatment efficacy.
-
Growth of Next-Generation Sequencing (NGS) Technology: NGS technology is revolutionizing genomic testing by providing comprehensive and high-throughput genetic information. The ability of NGS to sequence large amounts of genetic material at a relatively low cost is making it increasingly popular for lung cancer genomic testing, particularly for detecting multiple mutations simultaneously.
-
Shift Toward Personalized Medicine: The focus on personalized or precision medicine is growing rapidly within the lung cancer space. Genomic testing is a key enabler of personalized treatments, helping to tailor therapies based on the specific genetic makeup of a patient’s cancer. This approach not only improves treatment outcomes but also reduces the risk of adverse effects associated with traditional, one-size-fits-all therapies.
Market Size and Growth Projections:
The global lung cancer genomic testing market is set for remarkable growth, driven by technological advancements, rising awareness about the benefits of early cancer detection, and the growing demand for personalized treatment options. The market is projected to grow from USD 1.31 billion in 2024 to USD 2.47 billion by 2032. This significant expansion is attributed to several factors, including the increasing incidence of lung cancer worldwide, the rise in government funding for cancer research, and the introduction of innovative genomic testing products and services.
Key Market Growth Factors:
-
Rising Lung Cancer Incidence: The growing prevalence of lung cancer globally is one of the key factors driving the demand for genomic testing. As lung cancer remains one of the leading causes of cancer-related deaths, the need for advanced diagnostic tools that can provide insights into the genetic underpinnings of the disease has become crucial.
-
Technological Advancements in Genomic Testing: The ongoing developments in genomic technologies, particularly NGS and PCR, are enhancing the accuracy and efficiency of lung cancer testing. These advancements are expected to reduce the costs associated with genomic testing and make it more accessible to healthcare providers and patients.
-
Increasing Focus on Early Detection and Personalized Treatment: As healthcare systems shift towards precision medicine, the demand for genomic testing to identify molecular biomarkers for lung cancer is growing. Genomic tests are increasingly being used to personalize treatment plans, leading to better outcomes and fewer side effects for patients.
Key Market Opportunities:
-
Expanding Market in Emerging Regions: The growing healthcare infrastructure in regions such as Asia Pacific presents a significant opportunity for the lung cancer genomic testing market. As the region experiences rapid economic growth and improved access to healthcare, the adoption of genomic testing services is expected to rise sharply.
-
Emerging Biomarkers and New Technologies: The identification of new genetic biomarkers and the development of innovative technologies for lung cancer testing present significant opportunities for market players. These innovations can lead to the creation of more advanced and effective testing solutions, further driving market expansion.
-
Strategic Partnerships and Collaborations: Companies in the lung cancer genomic testing market can benefit from strategic collaborations and partnerships with research organizations, healthcare providers, and technology developers. Such partnerships can enhance product offerings and accelerate the commercialization of advanced genomic testing solutions.
Market Segmentation:
-
By Type:
- Products
- Services
-
By Technology:
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Fluorescence in Situ Hybridization (FISH)
-
By Sample Type:
- Tissue Biopsy
- Liquid Biopsy
-
By Panel Type:
- Multi-Gene Panels
- Single-Gene Panels
-
By End-User:
- Research Organizations
- Hospitals/Clinics
- Diagnostic Laboratories
Access Detailed Segmentation @ https://straitsresearch.com/report/lung-cancer-genomic-testing-market/segmentation
Key Players in the Lung Cancer Genomic Testing Market:
- QIAGEN N.V.
- Agilent Technologies, Inc.
- Thermo Fisher Scientific, Inc.
- Quest Diagnostics Incorporated
- Laboratory Corporation of America Holdings
- CENTOGENE N.V.
- BGI
- CeGaT GmbH
- Illumina, Inc.
- Hoffmann-La Roche Ltd.
- Abbott Laboratories
- CD Genomics
- NeoGenomics Laboratories
- Admera Health
- OncoDNA
- OPKO Health, Inc.
- Invitae Corporation
- Veracyte, Inc.
Dominated Region: North America North America holds the largest share of the lung cancer genomic testing market due to advanced healthcare infrastructure, high demand for personalized medicine, and the presence of key market players. The region also benefits from extensive research and development activities, fostering innovation in genomic testing technologies.
Fastest Growing Region: Asia Pacific The Asia Pacific region is expected to witness the fastest growth during the forecast period. The increasing incidence of lung cancer, improving healthcare infrastructure, and growing awareness about the benefits of genomic testing contribute to the region’s rapid market expansion.
For More Information, Queries, or Customization Before Buying, Visit @ https://straitsresearch.com/buy-now/lung-cancer-genomic-testing-market
The report offers in-depth insights into the global lung cancer genomic testing market, highlighting the factors that drive growth and offering strategic recommendations for market participants.
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian